The abilities of selected cytokines to activate human peripheral blood mononuclear cells (PBMC) to inhibit and kill the opportunistic fungus Cryptococcus neoformans were studied. PBMC were cultured for 7 days in cell wells containing no cytokines, tumor necrosis factor (TNF), gamma interferon (IFN-y), 1,25-dihydroxycholecalciferol (vitamin D3), granulocyte-macrophage colony-stimulating factor (GM-CSF), or interleukin-2 (IL-2) and were then challenged for 24 h with a fixed number of CFU of C. neoformans. The number of CFU increased in wells containing no cytokines, TNF, IFN-y, or vitamin D3 and remained about the same in wells containing GM-CSF. In contrast, the number of CFU in wells containing IL-2-stimulated PBMC decreased, suggesting fungicidal activity.
Impaired cell-mediated immunity predisposes patients to infections with the encapsulated fungus Cryptococcus neoformans (3, 22) . Clinical and experimental evidence suggests that lymphocytes and macrophages are necessary for optimnal antifungal activity (3, 5, 8, 11, 14, 16, 20) . However, the specific phenotypes of immune cells that are critical and the mechanisms by which these immune cells are activated remain to be determined. The availability of highly purified recombinant and synthetic cytokines has made possible studies examining whether physiological or pharmacological amounts of cytokines can activate specific effector cell populations to inhibit or kill C. neoformans. Such studies provide insights into how the normal immune system controls C. neoformans infection, and they may provide a rationale for immunotherapy of this difficult-to-treat fungal infection.
While gamma interferon (IFN-y) has been shown to activate mouse macrophage populations to kill C. neoformans (5, 11) , previous studies have failed to demonstrate the capacity of cytokines to activate human effector cells for enhanced activity against C. neoformans. IFN-y, tumor necrosis factor (TNF), granulocyte-macrophage colonystimulating factor (GM-CSF), and vitamin D3 each failed to stimulate human monocyte-derived macrophages for enhanced antifungal activity (13) . Similarly, the combination of interleukin-2 (IL-2) and IFN-a had no effect on the ability of purified human natural killer (NK) cells to inhibit C. neoformans (19) . These (6, 10) . Fungi were harvested from 4-day-old cultures that had been grown on asparagine minimal agar medium, as in previous studies (11) (12) (13) (14) (15) . Under these conditions, >95% of the C. neoformans isolates were present as single cells, viability of the cells as measured by a microcolony assay averaged >98%, and clumping of organisms was not observed (14) . The average capsule thickness on the encapsulated strain was 1.5 ,um (13 Separation of PBMC into adherent and nonadherent populations. Cultured PBMC were separated on the basis of their adherence to plastic, as in prior studies (14) . Briefly, PBMC (2 x 106) were cultured for 7 days in cell wells containing IL-2. Wells were then agitated, and the medium containing the suspended nonadherent cells was transferred to a new well. The transfer procedure was repeated two more times. Fresh medium containing IL-2 was added to the wells, and the cells were then challenged with live C.
neoformans. Antifungal activity was determined as outlined below.
Antifungal activity of cultured PBMC. Antifungal activity was determined as described previously (13, 14) . Pooled human serum (final concentration, 10%), 5 x 103 CFU of C. neoformans, and, where indicated, anticapsular antibody were added to each well. Wells were incubated an additional 24 h in a 37°C, 5% CO2 atmosphere. CFU of C. neoformans were then determined by sonication, dilution, and spread plating. For each experiment, two sets of cell wells containing C. neoformans, medium, and pooled human serum but no PBMC were included. The first set was sonicated, diluted, and plated immediately. The CFU counted were used to calculate the inoculum of live organisms added per well. The second set was incubated at 37°C for 24 h before being processed and plated. The CFU counted were used to calculate fungal replication in medium not containing PBMC. The growth of controls was not affected by anticapsular antibody.
Results are expressed as percent change in the experimental group from the inoculum according to the following formula: [(CFU in experimental sample/CFU in inoculum) - 1] x 100. Therefore, a negative value indicates that there were fewer live fungi in the experimental group than in the inoculum and that killing had taken place. However, because some of the yeast cells may have replicated while others were killed, the exact amount of killing cannot be calculated. Thus, a result of -20% means that a minimum of 20% of fungi in the inoculum were killed. A positive value indicates that there were more live fungi in the experimental group than in the inoculum and therefore that fungal replication had ensued. A value of zero indicates that the numbers of CFU at the start and the conclusion of the experiment were the same (14) .
Statistics. The means and standard error (SE) of sample groups were compared by the two-sample, two-tailed Student t test. 
RESULTS
In initial experiments, I examined the anticryptococcal activity of PBMC stimulated in culture by various cytokines (Fig. 1) . Both encapsulated and acapsular strains of C. neoformans were studied. Overall, fungal replication occurred when the encapsulated strain was incubated with unstimulated PBMC in both the presence and the absence of anticryptococcal antibody. However, the degree of fungal replication, as measured by the percent change in the inoculum, was significantly less in wells containing PBMC than in wells containing medium alone (186% versus 799%, respectively, P < 0.001). The degree of fungal replication detected in wells containing PBMC stimulated with 500 U of IFN--y per ml, of 500 U of TNF per ml, or 5 puM vitamin D3 was similar to that seen in wells containing unstimulated PBMC. In contrast, the number of CFU of C. neoformans in wells containing PBMC stimulated with 250 pM GM-CSF remained approximately constant during the 24-h incubation (P < 10-4, comparing PBMC stimulated without cytokines versus PBMC stimulated with GM-CSF). Moreover, there was a decrement in the number of CFU following incubation of encapsulated C. neoformans with PBMC stimulated with 100 U of IL-2 per ml, suggesting that overall fungal killing had taken place (P < 10-4, comparing PBMC stimulated without cytokines versus PBMC stimulated with IL-2). Consistent with results of previous studies (14) , the acapsular strain of C. neoformans was killed by unstimulated PBMC. Killing of the acapsular strain was significantly augmented in the presence of IL-2 (P = 0.015).
Since Figure 2 depicts the influence of IL-2 concentration on PBMC antifungal activity. IL-2 concentrations ranging from 0.1 to 1,000 U/ml were tested. In both the presence and the absence of anticryptococcal antibody, significant augmentation of PBMC antifungal activity was seen with IL-2 concentrations of 10, 100, and 1,000 U/ml. However, optimal results were obtained with 100 U/ml. This concentration was used for subsequent experiments.
The effect of the duration of IL-2 treatment on antifungal activity of cultured PBMC was examined next (Fig. 3) . The length of time of exposure of PBMC to IL-2 was varied from 2 h to 7 days. Even stimulation of PBMC with IL-2 for only 2 h prior to fungal challenge resulted in some beneficial effect, as the percent increase in the inoculum was diminished compared with that seen with unstimulated PBMC (P = 0.002). To demonstrate an overall reduction in CFU, a minimum of 5 days of incubation of PBMC with IL-2 was required.
The effect of varying the ratio of IL-2-stimulated PBMC to C. neoformans was studied next (Fig. 4) Finally, preliminary characterization of the nature of the IL-2-induced effector cells was attempted. IL-2-stimulated PBMC were separated on the basis of their adherence to plastic. Preliminary studies established that >90% of the adherent cells were of monocyte-macrophage lineage on the basis of their morphology and their capacity to phagocytose antibody-coated particles. Approximately the same degree of antifungal activity was seen in the nonadherent fraction as was seen in the unfractionated cells (Fig. 5) . In contrast, the adherent fraction had significantly diminished antifungal capacity. These effects were seen even when the numbers of adherent and nonadherent cells per well were equalized (data not shown).
DISCUSSION
The lymphocytotropic cytokine IL-2 is critical for the generation of an effective immune response (26) . IL-2 is required for clonal T-cell proliferation after antigen stimulation and for B-cell differentiation into antibody-secreting cells (26, 27) . In response to pharmacological concentrations of IL-2, specific lymphocyte populations proliferate and differentiate into lymphokine-activated killer cells capable of mediating non-major histocompatibility complex-restricted cytotoxicity against a broad array of tumor targets (4, 23, 29) . The data presented here establish that IL-2 is competent to activate PBMC to inhibit and probably kill C. neofor- mans. Optimal conditions for antifungal activity included a minimum of 5 days of incubation of PBMC with IL-2, a concentration of 100 U of IL-2 per ml, and a high ratio of PBMC to fungi.
Lymphokine-activated killer cells are a phenotypically heterogeneous group of cells, including those derived from NK-cell precursors (CD3-CD56+ CD16+) and from T-cell precursors (CD3+ CD56+ and CD3+ CD56-) (4, 7, 23, 28, 29) . There are significant differences between the requirements for activating PBMC with IL-2 to kill tumor targets and the requirements for activation to kill C. neoformans. For example, whereas IL-2 activates PBMC for tumoricidal activity within 3 days (28, 29) , activation for optimal antifungal activity took at least 5 days (Fig. 3) . Moreover, whereas 1,000 U of IL-2 per ml is an optimal or near optimal concentration for activating PBMC to kill tumor targets (29) , 100 U/ml proved to be ideal for fungal targets (Fig. 2) . Both length of culture periods and concentration of IL-2 influence the phenotypes of lymphocytes cultured with IL-2. Thus, longer culture periods result in a higher percentage of lymphocytes expressing CD3 (24, 30) . In addition, incubation with 100 U of IL-2 per ml favors expansion of CD4+ cells, while a concentration of 1,000 U/ml preferentially expands CD8+ cells (30) . The (14, 18) . However, it is not known whether the concentrations of IL-2 reached in tissue sites infected by C. neoformans in vivo are sufficient for activation of fungicidal effector cells. Moreover, the specific cells recruited to aid infected tissue in response to cryptococcal antigens may be incapable of IL-2-stimulated fungicidal activity. Patients at increased risk for cryptococcosis, especially those with AIDS, often have severe defects in their ability to produce IL-2 (21, 25). The studies presented here, although preliminary, support the possibility that IL-2, either as immunoprophylaxis or as immunotherapy, could be beneficial in such patients.
In addition to IL-2, GM-CSF had a beneficial effect, as the number of CFU of C. neoformans did not significantly increase in wells containing PBMC stimulated by GM-CSF (Fig. 1) . Future tifungal activity and the optimal conditions for their activation. In previous studies, GM-CSF failed to activate monocyte-derived macrophages to inhibit cryptococcal growth (13) . The other cytokines tested did not augment the antifungal activity of PBMC.
Thus, the data presented here demonstrate that IL-2, under defined conditions, is capable of activating PBMC to inhibit and probably kill C. neoformans. Antifungal activity was mediated by nonadherent cells, although the specific phenotypes of the responsible effector cells remain to be determined. In addition, these data suggest that IL-2 and GM-CSF may play a physiological and/or pharmacological role in host defenses against cryptococcosis.
